

**DRAFT AGENDA**  
**Council Meeting**  
**ALBERTA COLLEGE OF PHARMACISTS**  
**Monday, November 30 – Tuesday, December 1, 2015**  
**British Columbia Room, Westin Hotel,**  
**Edmonton, Alberta**

---

---

**1. Introduction**

**1.1 Call to Order**

**1.2 Roll Call**

**1.3 Invocation**

**1.4 Adoption of the Agenda**

**1.4.1 Consent Agenda**

**1.4.2 Additions to the Agenda**

**1.5 Minutes from Previous Meetings**

**1.5.1 Minutes – September 23 & 25, 2015**

**1.6 Disposition of Directives**

**1.7 In Camera**

**2. Governance**

**2.1 ENDS Policies and Reports**

**2.1.1 E-2 Resource Allocation**

**2.2 Compliance Monitoring and Reports**

**2.2.1 Executive Limitations – Compliance Reports**

**2.2.1.1 EL-3 Financial Planning - 3-Year Business Plan and Budget 2016**

**2.2.1.2 EL-4 Financial Condition (Internal)**

**2.2.1.3 EL-4 Financial Condition (External)**

**2.2.1.4 EL-6 Investments**

**2.2.2 Governance Policies (GP) – Compliance Reports**

**2.2.2.1 GP-7 Council and Committee Expenses**

**2.2.2.2 GP-13 Handling of Alleged Policy Violations**

**2.2.2.3 GP-14 Criteria for Awards**

**2.2.3 Council-Registrar Relationship Policies (CR) Compliance Reports**

**2.2.3.1 CR-1 Global Council-Registrar Relationship**

**2.3. Policy Review and Amendment**

**2.3.1 GP Policies–Policy Review and Amendment**

**2.3.1.1 GP-7 Council and Committee Expenses**

This will be addressed concurrent with Agenda Item 2.2.1.1.

**2.3.2 CR Policies – Policy Review and Amendment**

**2.3.2.1 CR-1 Global Council-Registrar Relationship**

**2.3.2.2 CR-2 Direction from Council**

**2.3.2.3 CR-3 Accountability of the Registrar**

**2.4 Ownership Linkage**

**2.4.1 Engagement with Albertans since Last Meeting**

**2.5 Report from the Resolutions Committee**

**2.6 Pharmacist Registrant Survey 2015**

**3. Legislated Responsibilities**

**3.1 Hearing Tribunal Decisions**

**3.1.1 Joyce Chen Pon - Registration Number 3726**

**3.2 Amendments to the Scheduled Drugs Regulation**

**3.3 Scheduling of Naloxone**

**3.4 Physician Assisted Dying**

**4. Miscellaneous Business for Council's Consideration**

**4.1 Report from the PEBC**

**4.2 Report from NAPRA**

**4.3 Report from APSA**

**4.4 Practice Research – Impacting Chronic Diseases, Dr. Ross Tsuyuki**

- 4.5 Report from Dr. Christine Hughes and Terri Schindel – Research Project Update - Perceptions of Pharmacists' Role and Professional Development Needs in the Era of Expanding Scopes of Practice**
- 4.6 Report from External Engagements**
  - 4.6.1 FIP Congress and British Health Agencies**
  - 4.6.2 Right Touch Thinking**
  - 4.6.3 Cameron Institute – Health Policy Assembly**
- 4.7 Pharmacy Strategic Roadmap**
- 4.8 Maximum Financial, Court of Queen’s Bench Decision**
- 4.9 “Unleashing Innovation: Excellent Healthcare for Canada” – Naylor Report to the Minister of Health 2015**
- 4.10 Pharmacare – What is ACP’s Role and How may ACP be Impacted?**

<b>5. Evaluation of Meeting</b>
---------------------------------

- 5.1 Self-Evaluation of Council Performance at this Meeting**
- 5.2 Summary of Results for the September 2015 Council Meeting**

<b>6. Adjournment</b>
-----------------------

- 6.1 Forthcoming Events and Council Meeting Dates**
  - 6.1.1 March 3-4, 2016 – Council Meeting**
  - 6.1.2 March 3, 2016 – APEX Awards**
  - 6.1.3 May 11, 2016 – Council Meeting**
  - 6.1.4 May 12-13, 2016 – ACP Leadership Forum**
  - 6.1.5 June 23-24, 2016 – Council Meeting**
  - 6.1.6 June 23, 2016 – Celebration of Leadership/Installation of President**
  - 6.1.7 June 25-27, 2016 – CPhA Conference**
- 6.2 Adjournment**